Congress orders urgent study of hair straighteners and cancer risk
H.R. 4396 — Uterine Cancer Study Act of 2025 · Filed by Yvette Clarke (D-NY) · 38 cosponsors · Introduced Jul 15, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Health and Human Services, working with the FDA and National Institutes of Health, to conduct a comprehensive study on whether chemical hair straighteners increase the risk of uterine cancer, with particular attention to higher rates among women of color. The study must review existing research, examine different product formulations (dyes, bleach, perms), and determine whether the FDA should require additional safety testing before these products reach consumers.
Why we flagged it
The bill's sole function is to authorize and fund a federally-directed epidemiological study on a specific consumer product and health outcome. It is a straightforward public-health research directive with no appropriations rider, tax provision, or regulatory carve-out.
What the text implies
- Study results may trigger FDA enforcement action or new product labeling requirements, potentially restricting market access for hair straightener manufacturers that cannot meet new safety standards.
- Disaggregated data by product type (dyes, bleach, perms) may reveal that certain formulations carry higher risk, leading to selective bans or reformulation mandates.
The full analysis lists 4 implications of this text.
Who stands to gain
Research institutions and universities (study contract awards); NIH and HHS contractors (data collection, analysis)